FDA Clears AI-Powered Fetal Ultrasound Analysis Software from DeepEcho
The AI software reportedly facilitates ease of use and improved accuracy in fetal ultrasound evaluations.
The Food and Drug Administration (FDA) has granted 510(k) clearance for an emerging artificial intelligence (AI)-enabled software to enhance fetal ultrasound assessment.
The DeepEcho AI software provides biometric measurement calculations through automated segmentation of anatomical landmarks, according to DeepEcho.
Emphasizing ease of use and accessibility for clinicians, DeepEcho said its recently FDA-cleared AI software enables one to collect the relevant fetal biometry images and planes with three short video loops. (Image courtesy of DeepEcho.)
Emphasizing ease of use and accessibility for clinicians, DeepEcho said the AI software enables one to collect the relevant fetal biometry images and planes with three short video loops. Through selection of the appropriate planes and suggested measurements, the AI software facilitates greater than 95 percent accuracy, according to DeepEcho.
"This milestone underscores the power of combining AI with clinical expertise to solve some of the most critical problems in healthcare," added Saad Slimani, M.D., M.S., co-founder and chief medical officer of DeepEcho. "With this FDA clearance, we are one step closer to making early, accurate prenatal diagnosis universally accessible and helping clinicians deliver better outcomes for families."
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
